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Abstract
Background: Cardiovascular diseases are the major cause of death in the world. Current treatments have not been
able to reverse this scenario, creating the need for the development of new therapies. Cell therapies have emerged as
an alternative for cardiac diseases of distinct causes in experimental animal studies and more recently in clinical trials.
Method/Design:  We have designed clinical trials to test for the efficacy of autologous bone marrow derived
mononuclear cell therapies in four different cardiopathies: acute and chronic ischemic heart disease, and Chagasic and
dilated cardiomyopathy. All trials are multicenter, randomized, double-blind and placebo controlled. In each trial 300
patients will be enrolled and receive optimized therapy for their specific condition. Additionally, half of the patients will
receive the autologous bone marrow cells while the other half will receive placebo (saline with 5% autologous serum).
For each trial there are specific inclusion and exclusion criteria and the method for cell delivery is intramyocardial for
the chronic ischemic heart disease and intracoronary for all others. Primary endpoint for all studies will be the difference
in ejection fraction (determined by Simpson's rule) six and twelve months after intervention in relation to the basal
ejection fraction. The main hypothesis of this study is that the patients who receive the autologous bone-marrow stem
cell implant will have after a 6 month follow-up a mean increase of 5% in absolute left ventricular ejection fraction in
comparison with the control group.
Discussion: Many phase I clinical trials using cell therapy for cardiac diseases have already been performed. The few
randomized studies have yielded conflicting results, rendering necessary larger well controlled trials to test for efficacy
of cell therapies in cardiopathies.
The trials registration numbers at the NIH registry are the following: Chagasic cardiomyopathy (NCT00349271), dilated 
cardiomyopathy (NCT00333827), acute myocardial infarction (NCT00350766) and Chronic Ischemic Heart Disease 
(NCT00362388).
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Background
Mortality from acute myocardial infarction has decreased
dramatically over the years due to improved interven-
tional therapy and adjunctive pharmacological treatment.
On the other hand the incidence of heart failure has
grown steadily reaching epidemic proportions. At its
advanced stages, heart failure leads to a poor quality of life
with severe restrictions to patients' daily activities and
high costs to the health system in face of the constant need
for hospitalizations.
The pathological basis of heart failure is cardiomyocyte
death, which may compromise the efficiency of the heart
as a pump. End-stage heart failure usually requires more
aggressive treatment such as heart transplantation, a
rather limited therapeutic option because of donor short-
age and high medical costs. In this scenario, new therapies
are clearly needed and cell-based therapies emerge as an
alternative.
There is growing evidence from animal experimental stud-
ies and initial clinical trials that cell therapy may be effec-
tive in ameliorating the burden of different cardiopathies
– for a review see [1]. In this article, we describe the design
of an ongoing clinical trial sponsored by the Brazilian
Ministry of Health, aiming to test the efficacy of bone
marrow-derived cell therapies in the treatment of four dif-
ferent cardiopathies.
The Multicenter Randomized Cell Therapy Trial in Cardi-
opathies (MiHeart) is, in fact, composed of four inde-
pendent clinical trials each one dealing with a specific
cardiopathy, namely: Chagasic cardiomyopathy
(NCT00349271), dilated cardiomyopathy
(NCT00333827), acute myocardial infarction
(NCT00350766) and chronic ischemic heart disease
(NCT00362388).
Each clinical trial is coordinated by a so-called "anchor
center", a medical institution with recognized undisputa-
ble tradition in clinical research, and a variable number of
collaborating centers that have to be licensed by the
anchor center. The collaborating centers are required to
have large experience in the treatment of the targeted dis-
ease and will participate in selection and follow-up of the
patients enrolled, as well as, after adequate training, in
performing the autologous bone-marrow stem cell
implant. A center may participate in more than one clini-
cal trial as long as it meets the requirements set by the
anchor centers. However, a given institution can only
anchor one of the clinical trials. Overall there are 40 Insti-
tutions participating in the study. The study has a
National Coordination, responsible for the online data
acquisition and analysis of all four clinical trials through
electronic case report forms (CRFs), located at the
National Cardiology Institute, an institution directly affil-
iated to the Ministry of Health. The Steering Committee of
the study is composed by two members of each anchor
center, two members of the central coordination, two rep-
resentatives of the Ministry of Health and two representa-
tives of the Ministry of Science and Technology. There is
also a Safety Committee composed of six medical doctors,
of which at least three are cardiologists, and who are not
involved in any aspect of the clinical trials.
The main hypothesis of this study is that patients who
receive the autologous bone-marrow stem cell implants
will have a mean absolute increase of 5% in left ventricu-
lar ejection fraction compared with the control group, 6
months after the procedure.
Methods/Design
All 4 trials were designed as multicenter, randomized,
double-blind, and placebo-controlled. The primary end-
point, common to all four trials, is the difference between
LV ejection fraction (determined by Simpson's rule) at six
and twelve months after intervention and baseline. Sec-
ondary endpoints are:
￿ Death by any cause within 1 year of intervention.
￿ Maximum oxygen consumption difference, as measured
by ergoespirometry, at six and twelve months compared
to baseline.
￿ Difference in quality of life as assessed by the Minnesota
Living with Heart Failure Questionnaire at six and twelve
months and baseline.
￿ Difference in NYHA functional class at six and twelve
months and baseline.
￿ Percentage of patients that reached an absolute increase
of 5% in LV ejection fraction at six and twelve months.
￿ Cost-effectiveness of autologous bone-marrow stem cell
implant in comparison with the control group in one
year.
For all clinical trials the safety endpoints are:
￿ Incidence of arrhythmias and conduction disturbances:
❍ Number of ventricular extra systoles in six months and
one year.
❍ Number of sustained ventricular tachycardia episodes
in six months and one year.Trials 2007, 8:2 http://www.trialsjournal.com/content/8/1/2
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❍ Number of non sustained ventricular tachycardia epi-
sodes in six months and one year.
❍ Incidence of atrial fibrillation in six months and one
year.
❍ New-onset of atrioventricular or intraventricular con-
duction disturbances.
❍ Need for artificial pacemaker implantation.
Each clinical trial has also tertiary endpoints which are not
described in this article but are currently available at the
NIH site.
The major inclusion criteria in all 4 studies are summa-
rized in Table 1. Other inclusion and exclusion criteria for
each specific study are not displayed in the Table but can
be assessed at the NIH site.
The sample size calculation for the trials was based on the
following assumptions:
￿ Based on data analysis of patients treated in the National
Cardiology Institute with heart failure and in NYHA class
III and IV in the last two years, we estimated a Gaussian
distribution for the left ventricular ejection fraction with a
mean value of 25% and standard deviation of 10%. These
values were taken as reference for the dilated and Chagasic
patients.
￿ Based on data analysis of patients treated at the Pro-
cardíaco Hospital with ischemic heart disease and class II-
IV CCS in the last two years, we estimated a Gaussian dis-
tribution for the left ventricular ejection fraction with a
mean value of 38% and a standard deviation of 14.1%.
These values were taken as reference for the ischemic
patients.
￿ After examining the literature it is reasonable to assume
an improvement of 5% in ejection fraction after cell ther-
apy.
￿ A panel of specialists evaluated that for the type of
patient enrolled in this study a gain of 5% in ejection frac-
tion could result in a significant clinical improvement.
Based on these assumptions, we estimate that to detect a
5% difference in ejection fraction with 95% confidence
(1-α) and 80% power (1-β) and a standard deviation of
15% (a larger sd was used to accommodate for the multi-
center character of the trial), we will need 142 patients.
Considering a 5% loss within 12 months of follow-up, we
ended up with 150 patients in each study arm and 300
patients in each trial.
All patient data are filed online by e-CRFs through soft-
ware specially developed for each trial according to Title
21 Code of Federal Regulations – part 11 [2]. The data
storage uses four mirror servers, two as web-servers and
two as database servers. The whole computational system
is duplicated in another area of the city. Detailed proto-
cols, all the CRFs, the informed consent and standard
operational procedures for marrow aspiration, mononu-
clear cell processing and catheterization for cell delivery
are available in Portuguese [3].
Software was created in R version 1.9.0 to specifically gen-
erate the randomization sequence for the study. It is
known that a simple randomization is sufficient and effi-
cient to render the study groups homogeneous for known
and unknown factors in large scale clinical trials. However
in smaller trials restriction techniques are recommended.
To insure homogeneity in the two arms of the study we
adopted block randomization. We will use randomiza-
tion by variable size block (blocks of 2, 4 or 6 patients).
Patients are randomized after bone marrow aspiration
and only the hematologist responsible for cell separation
has the login and password to randomize the patient
online. According to the assigned group, darkened
syringes containing the mononuclear cell fraction or
saline with 5% autologous serum are then prepared and
sent for implant into the patients.
Discussion
Many phase I clinical trials using cell therapy for cardiac
diseases have already been performed. In Chagasic cardi-
omyopathy, we recently published the results of such a
Table 1: Major inclusion criteria for each of the four cardiopathies.
Inclusion Criteria Dilated Cardiomyopathy Chagas Disease Chronic Ischemic Heart Disease Myocardial Infarction
Age (years) 18 to 65 18 to 75 30 to 75 30 to 80
Diagnosis of target disease WHO criteria 2 serologic test typical angina with positive cardiac scintigraphy or MRI WHO criteria
Congestive heart failure III – IV NYHA III – IV NYHA no no
Ischemia no no II to IV CCS not mandatory
Left ventricular ejection fraction ≤35% ≤35% 25%–55% <50%
Method Simpson Simpson Simpson Dodge
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trial involving 28 patients in Brazil [4]. In dilated cardio-
myopathy we published a case report [5] and just finished
inclusion of 30 patients. This study showed the procedure
to be feasible and safe, leading us to proceed with the
larger randomized trial. In chronic ischemic heart disease
we have published four reports using different injection
routes and demonstrating the procedure to be safe and
potentially efficacious [6-9]. The largest number of phase
I clinical trials have been published in the setting of acute
myocardial infarction. A number of randomized studies
have also been performed in AMI [10-12] yielding con-
flicting results, and thus justifying the need for larger well
controlled trials to test for efficacy of cell therapies in all
cardiopathies.
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